Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome

SS Manda; MM Espersen; C Mapagu; N Bouantoun; J Boros; YE Chiew; S Srirangan; S Pattnaik; CJ Kennedy; AH Brand; DW Garsed; A Pandey; DDL Bowtell; N Lucas; D Xavier; S Mahboob; D Bucio-Noble; B Tully; PG Hains; PJ Robinson; Q Zhong; R Reddel; A DeFazio; RL Balleine

Journal article

Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome

SS Manda, MM Espersen, C Mapagu, N Bouantoun, J Boros, YE Chiew, S Srirangan, S Pattnaik, CJ Kennedy, AH Brand, DW Garsed, A Pandey, DDL Bowtell, N Lucas, D Xavier, S Mahboob, D Bucio-Noble, B Tully, PG Hains, PJ Robinson Show all

Npj Precision Oncology | Published : 2025

DOI: 10.1038/s41698-025-00911-y

Download PDF

Abstract

Improved biomarkers of treatment response are needed for patients with high-grade serous ovarian cancer (HGSC). A challenge is substantial anatomical site-to-site variation in expression. We completed data-independent acquisition–mass spectrometry (DIA-MS) analysis of 404 fresh frozen and 78 formalin-fixed, paraffin-embedded HGSC tissue samples from the ovary (adnexal) and a common secondary site (omentum) in 11 patients. This was compared with mutation testing, gene expression, and whole-genome copy number profiling. Proteins with relatively stable intra- and variable inter-individual expression (n = 1651), included a 52-protein module reflecting interferon-mediated tissue inflammation, ind..

View full abstract